Livtencity Use In Pregnancy & Lactation

Pregnancy: There are no data of maribavir use in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). LIVTENCITY is not recommended during pregnancy and in women of childbearing potential not using contraception.
Maribavir is not expected to affect the plasma concentrations of systemically acting oral contraceptive steroids (see Interactions).
Breast-feeding: It is unknown whether maribavir or its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment with LIVTENCITY.
Fertility: Fertility studies were not conducted in humans with LIVTENCITY. No effects on fertility or reproductive performance were noted in rats in a combined fertility and embryofoetal development study, however, a decrease in sperm straight line velocity was observed at doses ≥ 100 mg/kg/day (which is estimated to be < 1 times the human exposure at the recommended human dose [RHD]). There were no effects on reproductive organs in either males or females in nonclinical studies in rats and monkeys (see Pharmacology: Toxicology: Preclinical safety data under Actions).